Fidelity International’s Prime Medicine PRME Stock Holding History

Fidelity International’s Portfolio PRME Stock Details PRME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$401K	Sell	115,206 -396	-0.3%	-$1.51K	﹤0.01%	883
2025 Q4	$401K	Sell	115,602 -727	-0.6%	-$3.23K	﹤0.01%	878
2025 Q3	$644K	Sell	116,329 -941	-0.8%	-$3.82K	﹤0.01%	812
2025 Q2	$290K	Sell	117,270 -3,747	-3%	-$5.78K	﹤0.01%	830
2025 Q1	$241K	Hold	121,017	–	–	﹤0.01%	821
2024 Q4	$353K	Sell	121,017 -8,844	-7%	-$31K	﹤0.01%	813
2024 Q3	$503K	Sell	129,861 -8,415	-6%	-$39K	﹤0.01%	774
2024 Q2	$711K	Hold	138,276	–	–	﹤0.01%	736
2024 Q1	$968K	Sell	138,276 -8,666	-6%	-$65.7K	﹤0.01%	722
2023 Q4	$1.3M	Sell	146,942 -1,658,616	-92%	-$12.8M	﹤0.01%	691
2023 Q3	$17.2M	Hold	1,805,558	–	–	0.02%	425
2023 Q2	$26.5M	Hold	1,805,558	–	–	0.03%	375
2023 Q1	$22.2M	Hold	1,805,558	–	–	0.03%	379
2022 Q4	$33.5M	Buy	+1,805,558	New	+$32.6M	0.04%	345

Other funds holding PRME

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Fidelity International's PRME Position: Q1 2026 in Review

Fidelity International reduced its Prime Medicine (PRME) stake by 0.34% in Q1 2026, selling an estimated $1.51K and leaving 115,206 shares worth $401K. The position accounts for ﹤0.01% of the portfolio, ranked #883.

Fidelity International first reported a position in PRME in Q4 2022 and has held it in 14 quarters since. The position peaked at $33.5M in Q4 2022. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

Fidelity International held 115,206 shares of Prime Medicine worth $401K as of Q1 2026.
Fidelity International sold 396 Prime Medicine shares in Q1 2026, an estimated $1.51K.
Prime Medicine made up ﹤0.01% of Fidelity International's portfolio in Q1 2026, its #883 holding.
Fidelity International first reported a position in Prime Medicine in Q4 2022 and has held it in 14 quarters since.
Fidelity International's Prime Medicine position peaked at $33.5M in Q4 2022.
192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Fidelity International's 13F filing for Q1 2026, filed 15 May 2026.